Physician profile
Alexandre Nader
NPI 1518914100
$2,918.99
in general payments reported to CMS, 2019-2025
24 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,414 · 2020: $401 · 2021: $20.33 · 2022: $324 · 2023: $269 · 2024: $234 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.23 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $389.30 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $383.84 | 2019-2020 | |
| Janssen Biotech, INC. | $365.62 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Janssen Scientific Affairs, LLC | $351.79 | 2019-2022 | |
| Pfizer INC. | $254.52 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.04 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $168.08 | 2019 | |
| Madrigal Pharmaceuticals | $159.29 | 2024 | Rezdiffra, Resmetirom |
| Allergan, INC. | $110.32 | 2019-2020 | |
| Olympus America INC. | $89.77 | 2019-2020 | |
| Genzyme Corporation | $88.77 | 2023 | |
| Nestle Healthcare Nutrition INC. | $69.21 | 2021-2023 | |
| Braintree Laboratories, INC. | $56.84 | 2019 | |
| Shire North American Group INC | $33.24 | 2019 | |
| Phathom Pharmaceuticals, INC. | $25.37 | 2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $23.85 | 2020 | |
| Intercept Pharmaceuticals, INC. | $22.52 | 2020 | |
| Alfasigma USA, INC. | $22.07 | 2020 | |
| Aimmune Therapeutics, INC. | $19.44 | 2024 | |
| Qol Medical, LLC | $16.89 | 2019 | |
| Henry Schein, INC. | $16.41 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $14.09 | 2020 | |
| Ferring Pharmaceuticals INC. | $11.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandre Nader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.